[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Women and Vaccination |
|
|
Clinical Trial: Multiepitope Peptide Vaccination in Melanoma
This study is no longer recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Metastatic Melanoma | Vaccine: Tyrosinase, MAGE-3, GnTV | Phase II |
MedlinePlus related topics: Melanoma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase II Study of Multiepitope Peptide Vaccination in Combination with Adjuvants GM-CSF and KLH in Metastatic Melanoma
Secondary Outcomes: Immune response; Safety
Expected Total Enrollment: 25
Study start: March 2003
Last follow-up: September 2005
Eligibility
Inclusion Criteria:
- Metastatic melanoma
- HLA-A1, -A2, -A24, -B44
Exclusion Criteria:
Location Information
Germany
Hem&Onc Charité CBF, Berlin, 12200, Germany
Ulrich Keilholz, MD, Principal Investigator, Charité, CBF
More Information
Publications
Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer. 2003 Mar 20;104(2):188-94.
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00153569
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Women and Vaccination (Centers for Disease Control and Prevention)

Not Signed In -


